The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Safety and Efficacy of Anakinra in Severe Hidradenitis Suppurativa: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Hidradenitis suppurativa (HS) is a common skin disorder in which excessive inflammation is believed to have an important role. There is no specific therapy for HS. OBJECTIVE: To investigate the safety and efficacy of the anti-inflammatory biological therapy anakinra in HS. DESIGN, SETTING, AND PARTICIPANTS: Double-blind, randomized, placebo-controlled clinical trial with a 12-week treatment phase and a 12-week follow-up phase. The setting was Attikon University General Hospital, a tertiary care institution in Athens, Greece. Participants were 20 patients with Hurley stage II or III HS. The study and the analysis were conducted between March 1, 2012, and February 28, 2014. INTERVENTIONS: Patients were randomized to receive injections from identical syringes containing placebo or anakinra subcutaneously once daily for 12 weeks. Peripheral blood mononuclear cells were isolated and stimulated for cytokine production before the beginning of treatment and at week 12 (the end of treatment) and week 24. MAIN OUTCOMES AND MEASURES: The primary end point was the effect of anakinra on HS disease severity. Secondary end points were the time to a new exacerbation and the production of cytokines. RESULTS: Among the 20 trial participants, 10 each were randomized to the group to receive anakinra or the placebo group. The mean (SD) ages were 42.8 (13.8) and 36 (11.3) years in the anakinra and placebo groups, respectively. The disease activity score was decreased at the end of treatment in 20% (2 of 10) of the placebo arm compared with 67% (6 of 9) of the anakinra arm (P = .04). Hidradenitis suppurativa clinical response at 12 weeks was achieved in 30% (3 of 10) of the placebo arm and in 78% (7 of 9) of the anakinra arm (P = .04). The production of interferon-γ by peripheral blood mononuclear cells in the anakinra arm was decreased, and the production of interleukin 22 was increased. The time to a new HS exacerbation was prolonged in the anakinra arm by log-rank test (log rank, 6.137; P = .01). No serious adverse events were reported. CONCLUSIONS AND RELEVANCE: Anakinra has the potential to be an effective and well-tolerated treatment for HS. Inhibition of interleukin 1 is a promising treatment strategy. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01558375.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical power analyses using G∗Power 3.1: tests for correlation and regression analyses
Faul, F., Erdfelder, E., Buchner, A., & Lang, A.-G. (2009) · Behavior Research Methods · doi:10.3758/brm.41.4.1149 · Cited by 37,615
Dermatology Life Quality Index (DLQI)-a simple practical measure for routine clinical use
FINLAY, A. Y., & KHAN, G. K. (1994) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.1994.tb01167.x · Cited by 5,586
European S1 guideline for the treatment of hidradenitis suppurativa/acne inversa
Zouboulis, C. C., Desai, N., Emtestam, L., Hunger, R. E., Ioannides, D., Juhász, I., Lapins, J., Matusiak, L., Prens, E. P., Revuz, J., et al. (2015) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.12966 · Cited by 1,093
Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
Bresnihan, B., Alvaro-Gracia, J. M., Cobby, M., Doherty, M., Domljan, Z., Emery, P., Nuki, G., Pavelka, K., Rau, R., Rozman, B., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199812)41:12<2196::aid-art15>3.0.co;2-2 · Cited by 981
Jemec, G. B. E. (2012) · New England Journal of Medicine · doi:10.1056/nejmcp1014163 · Cited by 817
Revuz, J. E., Canoui-Poitrine, F., Wolkenstein, P., Viallette, C., Gabison, G., Pouget, F., Poli, F., Faye, O., Roujeau, J. C., Bonnelye, G., et al. (2008) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2008.06.020 · Cited by 627
van der Zee, H. H., de Ruiter, L., van den Broecke, D. G., Dik, W. A., Laman, J. D., & Prens, E. P. (2011) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2011.10254.x · Cited by 472
Kimball, A. B., Kerdel, F., Adams, D., Mrowietz, U., Gelfand, J. M., Gniadecki, R., Prens, E. P., Schlessinger, J., Zouboulis, C. C., van der Zee, H. H., et al. (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-12-201212180-00004 · Cited by 428
Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa
Schlapbach, C., Hänni, T., Yawalkar, N., & Hunger, R. E. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.07.010 · Cited by 425
Grant, A., Gonzalez, T., Montgomery, M. O., Cardenas, V., & Kerdel, F. A. (2010) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2009.06.050 · Cited by 419
Fleischmann, R. M., Schechtman, J., Bennett, R., Handel, M. L., Burmester, G., Tesser, J., Modafferi, D., Poulakos, J., & Sun, G. (2003) · Arthritis & Rheumatism · doi:10.1002/art.10870 · Cited by 392
Morbidity in patients with hidradenitis suppurativa
Von Der Werth, J. M., & Jemec, G. B. E. (2001) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2001.04137.x · Cited by 344
Braun‐Falco, M., Kovnerystyy, O., Lohse, P., & Ruzicka, T. (2011) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2010.12.025 · Cited by 318
What causes hidradenitis suppurativa?
Ralf Paus, L., Kurzen, H., Kurokawa, I., Jemec, G. B. E., Emtestam, L., Sellheyer, K., Giamarellos-Bourboulis, E. J., Nagy, I., Bechara, F. G., Sartorius, K., et al. (2008) · Experimental Dermatology · doi:10.1111/j.1600-0625.2008.00712.x · Cited by 269
Self-citationSartorius, K., Lapins, J., Emtestam, L., & Jemec, G. B. E. (2003) · British Journal of Dermatology · doi:10.1046/j.1365-2133.2003.05390.x · Cited by 252
Kimball, A. B., Jemec, G. B. E., Yang, M., Kageleiry, A., Signorovitch, J. E., Okun, M. M., Gu, Y., Wang, K., Mulani, P., & Sundaram, M. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13270 · Cited by 214
Blocking interleukin-1β in acute and chronic autoinflammatory diseases
Dinarello, C. A. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02313.x · Cited by 146
Self-citationAltered innate and adaptive immune responses in patients with hidradenitis suppurativa
Giamarellos‐Bourboulis, E. J., Antonopoulou, A., Petropoulou, C., Mouktaroudi, M., Spyridaki, E., Baziaka, F., Πελεκάνου, Α., Giamarellou, H., & Stavrianeas, N. G. (2006) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2006.07556.x · Cited by 125
Self-citationGiamarellos‐Bourboulis, E. J., Pelekanou, E., Antonopoulou, A., et al. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.08372.x · Cited by 124
Self-citationAn open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa
Leslie, K. S., Tripathi, S. V., Nguyen, T. V., Pauli, M. L., & Rosenblum, M. D. (2013) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2013.09.044 · Cited by 119
Hidradenitis Suppurativa and Concomitant Pyoderma Gangrenosum
Hsiao, J. L., Antaya, R. J., Berger, T. G., Maurer, T. A., Shinkai, K., & Leslie, K. S. (2010) · Archives of Dermatology · doi:10.1001/archdermatol.2010.328 · Cited by 106
Long-term Successful Adalimumab Therapy in Severe Hidradenitis Suppurativa
Blanco, R., Martínez-Taboada, V. M., Villa, I., Gonzaléz‐Vela, M. C., Fernández‐Llaca, H., Agudo, M., & González-López, M. A. (2009) · Archives of Dermatology · doi:10.1001/archdermatol.2009.49 · Cited by 90
Successful Treatment of Severe Hidradenitis Suppurativa With Anakinra
Zarchi, K., Dufour, D., & Jemec, G. B. E. (2013) · JAMA Dermatology · doi:10.1001/jamadermatol.2013.5377 · Cited by 73
Compartmentalized Cytokine Responses in Hidradenitis Suppurativa
Kanni, T., Tzanetakou, V., Savva, A., Kersten, B. E., Pistiki, A. C., van de Veerdonk, F. L., Netea, M. G., van der Meer, J. W., & Giamarellos‐Bourboulis, E. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130522 · Cited by 69
Self-citationFailure of Anti-Interleukin-1 Therapy in Severe Hidradenitis Suppurativa: A Case Report
van der Zee, H. H., & Prens, E. P. (2013) · Dermatology · doi:10.1159/000343221 · Cited by 65
Kanda, N., & Watanabe, S. (2011) · Immunobiology · doi:10.1016/j.imbio.2011.10.010 · Cited by 65
Two cases of severe hidradenitis suppurativa with failure of anakinra therapy
Menis, D., Maroñas‐Jiménez, L., Delgado‐Márquez, A. M., Postigo‐Llorente, C., & Vanaclocha-Sebastián, F. (2014) · British Journal of Dermatology · doi:10.1111/bjd.13292 · Cited by 42
Cited by
Interleukin-1 and Related Cytokines in the Regulation of Inflammation and Immunity
Mantovani, A., Dinarello, C. A., Molgora, M., & Garlanda, C. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.012 · Cited by 1,046
Self-citationSabat, R., Jemec, G. B. E., Matusiak, Ł., Kimball, A. B., Prens, E., & Wolk, K. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0149-1 · Cited by 573
Hidradenitis Suppurativa: Advances in Diagnosis and Treatment
Saunte, D. M. L., & Jemec, G. B. E. (2017) · JAMA · doi:10.1001/jama.2017.16691 · Cited by 492
Alikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.067 · Cited by 400
Alikhan, A., Sayed, C., Alavi, A., Alhusayen, R., Brassard, A., Burkhart, C., Crowell, K., Eisen, D. B., Gottlieb, A. B., Hamzavi, I., et al. (2019) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2019.02.068 · Cited by 399
Metadata
- Authors
- Tzanetakou, V., Kanni, T., Giatrakou, S., Katoulis, A., Papadavid, E., Netea, M. G., Dinarello, C. A., van der Meer, J. W. M., Rigopoulos, D., & Giamarellos-Bourboulis, E. J.
- Venue
- JAMA Dermatology
- Publisher
- American Medical Association (AMA)
- Published
- 2016-01-01
- Volume
- 152
- Issue
- 1
- Pages
- 52
- ISSN
- 2168-6068 (ISSN-L)
- OpenAlex
- W2175027747
- Cited by
- 266
- References
- 27
- FWCI
- 18.94
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.